Skip to content

Home
About
News
Investors
Contact

News

Firebrick launch on ASX receives national media attention

Firebrick launch on ASX receives national media attention

28 Jan 2022

19514

Recent Posts

Nasodine Phase 2 COVID-19 Trial Results Published
Nasodine COVID-19 patent granted
Nasal disinfection as a front-line defence in future pandemics
Firebrick Investor Update
Update on Nasodine Trial and Forward Plans

Archives

April 2024
November 2023
October 2023
August 2023
June 2023
May 2023
April 2023
March 2023
February 2023
January 2023
November 2022
October 2022
September 2022
May 2022
April 2022
March 2022
February 2022
January 2022

Subscribe to stay up to date with Firebrick

First name(Required)

Last name(Required)

Company or organisation

Enter your email(Required)

*Mandatory fields

13047

Privacy Policy
Terms & Conditions
Social Media and Website Usage Policy

Level 10, 440 Collins St, Melbourne VIC 3000| Phone: 1-300-301-874

Copyright © 2023 Firebrick Pharma Limited. All Rights Reserved.

Home
About
News
Investors
Contact